Posts by Replicor

MONTREAL, November 2nd, 2020 – Replicor Inc., a privately held biopharmaceutical company targeting functional cure for patients with chronic hepatitis B and D infection, announced the acceptance of four presentations at the 2020 digital meeting of the American Association for the Study of the Liver (AASLD / TLMdX) being held from November 13-16, 2020.These presentations…

MONTREAL, September 10th, 2020 – Replicor Inc., a privately held biopharmaceutical company targeting functional cure for patients with chronic hepatitis B and D infection, announced the late breaking presentation of experimental endpoint data from its most recent REP 301/301-LTF and REP 401 studies at the Digital ILC 2020. Conducted in collaboration with Abbott Diagnostics, a variety…

MONTREAL, June 23rd, 2020 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic HBV and hepatitis delta virus (HDV) co-infection, announces the publication of an expanded in vitro study of the antiviral effects of REP 2139 in HBV entitled “Characterization of the antiviral effects of REP…

MONTREAL, July 13th, 2020 – Replicor Inc., a privately held biopharmaceutical company targeting functional cure for patients with chronic hepatitis B and D infection, announced that Dr. Andrew Vaillant, CSO at Replicor, will present an overview of HBsAg in chronic HBV infection as part of the Online Research Seminars 2020 series hosted by the Baruch S.…

MONTREAL, May 12th, 2020 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic HBV and hepatitis delta virus (HDV) co-infection, today announced the publication of the modelling of antiviral responses to REP 2139 monotherapy in HBV / HDV co-infection in the journal Scientific Reports…

MONTREAL, March 9, 2020 – Replicor Inc., a privately held biopharmaceutical company targeting functional cure for patients with chronic hepatitis B and D infection, announced the publication of the final results of its latest REP 401 study in the prestigious journal Gastroenterology. The article, entitled “Safety and Efficacy of 48 Weeks REP 2139 or REP…

MONTREAL, December 5th, 2019 – Replicor Inc., a privately held biopharmaceutical company targeting functional cure for patients with chronic hepatitis B and D infection, announced that three presentations will be made at the 2019 HEPDART meeting to be held December 8-12th , 2019 in Kauai, HI, USA.One oral presentation on December 9th and two posters…

MONTREAL, July 29th, 2019 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic HBV and hepatitis delta virus (HDV) co-infection, today announced the publication of new data examining the evolution of HBsAg immunoreactivity during REP 2139 therapy in the Journal of Viral Hepatitis (https://onlinelibrary.wiley.com/doi/pdf/10.1111/jvh.13180).…

MONTREAL, June 10th, 2019 – Replicor Inc., a privately held biopharmaceutical company targeting functional cure for chronic hepatitis B and D patients, presented the final follow-up data from the REP 401 study assessing the impact of addition of REP 2139-Mg or REP 2165-Mg to an existing backbone therapy of TDF and pegylated interferon in participants…

MONTREAL, April 1st, 2019 – Replicor Inc., a privately held biopharmaceutical company targeting functional cure for chronic hepatitis B and D patients, today announced it will present data on the beneficial impact of transaminase flares in achieving HBV functional cure with REP 2139-Mg at the 2019 EASL International Liver Conference (ILC) to be held April 10th –…